Goldman Sachs’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $510K | Buy |
73,122
+42,014
| +135% | +$326K | ﹤0.01% | 5582 |
|
|
2025
Q4 | $220K | Buy |
31,108
+13,074
| +72% | +$101K | ﹤0.01% | 6006 |
|
|
2025
Q3 | $135K | Buy |
+18,034
| New | +$137K | ﹤0.01% | 6029 |
|
|
2025
Q2 | – | Sell |
-16,147
| Closed | -$125K | – | 6217 |
|
|
2025
Q1 | $125K | Sell |
16,147
-10,239
| -39% | -$112K | ﹤0.01% | 5743 |
|
|
2024
Q4 | $319K | Buy |
26,386
+7,587
| +40% | +$97.1K | ﹤0.01% | 5471 |
|
|
2024
Q3 | $236K | Buy |
+18,799
| New | +$242K | ﹤0.01% | 5396 |
|
|
2024
Q2 | – | Sell |
-46,093
| Closed | -$806K | – | 5760 |
|
|
2024
Q1 | $806K | Buy |
+46,093
| New | +$831K | ﹤0.01% | 4478 |
|
|
2023
Q2 | – | Sell |
-1,428
| Closed | -$4.43K | – | 5877 |
|
|
2023
Q1 | $4.43K | Buy |
+1,428
| New | +$5.43K | ﹤0.01% | 5803 |
|
|
2022
Q4 | – | Sell |
-12,179
| Closed | -$46K | – | 6108 |
|
|
2022
Q3 | $46K | Sell |
12,179
-3,707
| -23% | -$47.1K | ﹤0.01% | 5809 |
|
|
2022
Q2 | $212K | Buy |
15,886
+244
| +2% | +$1.62K | ﹤0.01% | 5616 |
|
|
2022
Q1 | $77K | Sell |
15,642
-16,439
| -51% | -$81.5K | ﹤0.01% | 6178 |
|
|
2021
Q4 | $220K | Buy |
32,081
+10,654
| +50% | +$182K | ﹤0.01% | 5843 |
|
|
2021
Q3 | $660K | Sell |
21,427
-13,371
| -38% | -$440K | ﹤0.01% | 5028 |
|
|
2021
Q2 | $1.13M | Sell |
34,798
-185
| -0.5% | -$6.35K | ﹤0.01% | 4674 |
|
|
2021
Q1 | $1.32M | Sell |
34,983
-946
| -3% | -$43.2K | ﹤0.01% | 4392 |
|
|
2020
Q4 | $1.7M | Buy |
35,929
+920
| +3% | +$39.8K | ﹤0.01% | 3836 |
|
|
2020
Q3 | $1.13M | Buy |
35,009
+13,952
| +66% | +$546K | ﹤0.01% | 3988 |
|
|
2020
Q2 | $927K | Sell |
21,057
-172
| -0.8% | -$8.08K | ﹤0.01% | 4004 |
|
|
2020
Q1 | $696K | Buy |
21,229
+16,516
| +350% | +$759K | ﹤0.01% | 4001 |
|
|
2019
Q4 | $241K | Sell |
4,713
-652
| -12% | -$27.3K | ﹤0.01% | 4829 |
|
|
2019
Q3 | $198K | Sell |
5,365
-11,916
| -69% | -$642K | ﹤0.01% | 4828 |
|
|
2019
Q2 | $955K | Buy |
17,281
+10,763
| +165% | +$673K | ﹤0.01% | 4029 |
|
|
2019
Q1 | $396K | Sell |
6,518
-825
| -11% | -$53K | ﹤0.01% | 4515 |
|
|
2018
Q4 | $435K | Buy |
7,343
+4,181
| +132% | +$308K | ﹤0.01% | 4438 |
|
|
2018
Q3 | $256K | Buy |
3,162
+1,669
| +112% | +$132K | ﹤0.01% | 4789 |
|
|
2018
Q2 | $131K | Sell |
1,493
-4,608
| -76% | -$808K | ﹤0.01% | 5130 |
|
|
2018
Q1 | $1.18M | Buy |
+6,101
| New | +$1.14M | ﹤0.01% | 3942 |
|
|
2017
Q1 | – | Sell |
-430
| Closed | -$31K | – | 6864 |
|
|
2016
Q4 | $31K | Buy |
430
+52
| +14% | +$4.68K | ﹤0.01% | 6525 |
|
|
2016
Q3 | $51K | Sell |
378
-71
| -16% | -$10.7K | ﹤0.01% | 6462 |
|
|
2016
Q2 | $77K | Buy |
449
+10
| +2% | +$1.71K | ﹤0.01% | 6248 |
|
|
2016
Q1 | $83K | Sell |
439
-33
| -7% | -$7.96K | ﹤0.01% | 6164 |
|
|
2015
Q4 | $166K | Sell |
472
-98
| -17% | -$38.5K | ﹤0.01% | 5840 |
|
|
2015
Q3 | $299K | Buy |
570
+472
| +482% | +$720K | ﹤0.01% | 5610 |
|
|
2015
Q2 | $216K | Sell |
98
-3
| -3% | -$6.01K | ﹤0.01% | 6077 |
|
|
2015
Q1 | $236K | Sell |
101
-27
| -21% | -$55.8K | ﹤0.01% | 5870 |
|
|
2014
Q4 | $266K | Sell |
128
-53
| -29% | -$102K | ﹤0.01% | 5900 |
|
|
2014
Q3 | $360K | Buy |
181
+31
| +21% | +$76.6K | ﹤0.01% | 5589 |
|
|
2014
Q2 | $532K | Sell |
150
-74
| -33% | -$241K | ﹤0.01% | 5256 |
|
|
2014
Q1 | $837K | Sell |
224
-283
| -56% | -$1.05M | ﹤0.01% | 4855 |
|
|
2013
Q4 | $1.66M | Buy |
507
+279
| +122% | +$1.1M | ﹤0.01% | 4268 |
|
|
2013
Q3 | $952K | Buy |
228
+67
| +42% | +$270K | ﹤0.01% | 4630 |
|
|
2013
Q2 | $542K | Buy |
+161
| New | +$613K | ﹤0.01% | 4877 |
|
Other funds holding GYRE
VCM
SS
VFT
VPM
Goldman Sachs's GYRE Position: Q1 2026 in Review
Goldman Sachs increased its Gyre Therapeutics (GYRE) stake by 135% in Q1 2026, buying an estimated $326K and bringing the position to 73,122 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #5582.
Goldman Sachs first reported a position in GYRE in Q2 2013 and has held it in 42 quarters since. The position peaked at $1.7M in Q4 2020. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.
- Goldman Sachs held 73,122 shares of Gyre Therapeutics worth $510K as of Q1 2026.
- Goldman Sachs bought 42,014 Gyre Therapeutics shares in Q1 2026, an estimated $326K.
- Gyre Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5582 holding.
- Goldman Sachs first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 42 quarters since.
- Goldman Sachs's Gyre Therapeutics position peaked at $1.7M in Q4 2020.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.